Close
Nordic 9Nordic 9

Cancer Research Horizons (investor - Corporate Investor)

United Kingdom cancerresearchhorizons.com
See something wrong or missing? Let us know
Offices:London

Cancer Research Horizons is a British specialist drug discovery, development and commercialisation company

Average round investment:24.35M USD
Average number per year:2.0
Distribution: 2026 (2)2025 (3)2024 (2)2023 (1)
Portfolio companies: Netherlands Laigo BioUnited Kingdom InfinitopesUnited Kingdom Verinnogen See the entire list
Mostly invests in: United Kingdom United Kingdom (6) Health services (7)
See the entire list

Showing 3 of 8 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Cancer Research Horizons

Name Criteria
Netherlands Main Capital Partners
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Manufacturing, Software Services
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
United States Neverlift Ventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Manufacturing, Software Services, Hardware
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
Denmark Lundbeckfond Ventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Pharma, Manufacturing, Software Services, Hardware, Biotech
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 2.1
  • Active last 12 months: Yes
United States Vertex Ventures US
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Manufacturing, Software Services, Hardware, Biotech
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 2.1
  • Active last 12 months: Yes
United States Adjuvant Capital
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Pharma, Manufacturing, Biotech
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 2.2
  • Active last 12 months: Yes
Germany TEV Ventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Manufacturing, Software Services, Hardware
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 2.2
  • Active last 12 months: Yes
France AdBio partners
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Pharma, Manufacturing, Biotech
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 2.2
  • Active last 12 months: Yes
United States Applied Ventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Manufacturing, Software Services, Hardware
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.6
  • Active last 12 months: Yes
United States Kindred Ventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Manufacturing, Software Services, Biotech
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 2.4
  • Active last 12 months: Yes
United States Lux ​​Capital
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Manufacturing, Software Services, Hardware, Biotech
  • Similar business models: B2B
  • Common investees countries: United Kingdom, Netherlands
  • Average number of deals per year: 2.5
  • Active last 12 months: Yes
Top